• A potent, specific inhibitor of the canonical Wnt signaling pathway in cancer stem cells that specifically inhibits the recruiting of β-catenin with its coactivator CBP (the binding protein of the cAMP response element-binding protein CREB).
    • Currently in phase 1 clinical trials for solid tumors and myeloid malignancies
    • Recommended dose: 905 mg/m2 IV infusion for 7 days on, 7 days off (14-day cycle)
    • Half-life: â™7 hours
    • Common side effects: Hyperbilirubinemia, diarrhea, hypophosphatemia, nausea, fatigue, anorexia, thrombocytopenia, ALP elevation
    (El-khoueiry et al., 2013)
    Other topics in Targeted and Immunotherapy Agents